Hosted on MSN
Alumis stock hits record high as Wall Street cheers phase 3 psoriasis 'win' — analysts see best-in-class potential
・Analysts lifted price targets and reaffirmed bullish ratings after the Phase 3 results. ・The new trial data showed strong skin clearance with results improving over time. ・Alumis outlined plans for ...
One day in early May, web-based prediction market platform Kalshi listed two contracts tied to Compass Pathways’ psilocybin ...
Evommune (EVMN) added more than ~50% in early trading on Tuesday after the biotech announced a mid-stage trial win for EVO301, its experimental therapy for atopic dermatitis, which is identified as ...
Hosted on MSN
MLTX stock jumps over 10% overnight as spine drug trial win sets stage for investor day showdown
Phase 2 S-OLARIS trial data showed 81% of patients improved within 12 weeks, meeting the primary endpoint. Imaging and biomarker results confirming reduced spine inflammation, while no new safety ...
Karyopharm Therapeutics (KPTI) announced plans to seek a label expansion for its lead asset, selinexor, on Tuesday after the oral treatment branded as Xpovio succeeded in a late-stage trial for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results